Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments
Top Cited Papers
- 4 July 2017
- journal article
- review article
- Published by IOS Press in Cancer Biomarkers
- Vol. 19 (4), 353-363
- https://doi.org/10.3233/cbm-160336
Abstract
Metabolism of neoplastic cells is shifted toward high glucose uptake and enhanced lactate production. Lactate dehydrogenase (LDH), which is comprised of two major subunits, LDH-A and LDH-B, reversibly catalyzes the conversion of pyruvate to lactate oThis publication has 54 references indexed in Scilit:
- Ovarian cancer progression is controlled by phenotypic changes in dendritic cellsThe Journal of Experimental Medicine, 2012
- Drug Resistance and Cellular Adaptation to Tumor Acidic pH MicroenvironmentMolecular Pharmaceutics, 2011
- Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironmentThe Journal of Experimental Medicine, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to TaxolMolecular Cancer, 2010
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progressionProceedings of the National Academy of Sciences of the United States of America, 2010
- LDHC: The Ultimate Testis‐Specific GeneJournal of Andrology, 2010
- Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor CellsThe Journal of Immunology, 2009
- Impact of Extracellular Acidity on the Activity of P-glycoprotein and the Cytotoxicity of Chemotherapeutic DrugsNeoplasia, 2006